ClinicalTrials.gg
CompletedNCT02814175CONTROLUpdated Nov 23, 2020Results posted

A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

A Phase 4 interventional study of methotrexate (MTX) and adalimumab (ADA) in Psoriatic Arthritis, sponsored by AbbVie. Completed at 60 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-23.

Sponsored by AbbVie · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
246
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing methotrexate in Arthritis, Psoriatic — 5 open to participants now, 5 under way, 1 of them phase 3. Methotrexate · Arthritis, Psoriatic.

Enrollment
3rd of 10
246 · median 112
Started
2016
with 1 other
Phase 4
3 of 10
1 open now
Registered
4th of 10
by date
Lead sponsor
1 of 10
AbbVie

Among the 10 studies testing methotrexate in Arthritis, Psoriatic, this one is the 3rd largest by enrollment, is one of 2 that started in 2016, is one of 3 in phase 4, and was the 4th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

5 of the 10 studies testing methotrexate in Arthritis, Psoriatic are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing methotrexate in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

An interventional Phase 4 open-label, randomized, controlled, parallel-group, multi-country study in participants with psoriatic arthritis (PsA) consisting of 2 parts: Part 1 (Day 1 up to Week 16) is designed to compare the achievement of minimal disease activity (MDA) between participants randomized to either adalimumab in combination with methotrexate (MTX) or MTX alone escalated to the highest recommended or tolerable dose; Part 2 (Week 16 through Week 32) is designed to evaluate the maintenance or achievement of MDA on 4 different treatment regimens using adalimumab and/or MTX, with participant allocation based on the initial randomized treatment and achievement of MDA in Part 1, and with rescue treatment option.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

Keywords

  • Psoriatic Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. PsA diagnosis established at least 4 weeks prior to the date of the Screening visit and confirmed by ClASsification of Psoriatic Arthritis (CASPAR) criteria
  2. Not in MDA at the time of screening
  3. Has 3 or more tender and 3 or more swollen joints
  4. Treated with methotrexate 15 mg (weekly) for at least 4 weeks

Exclusion criteria

Exclusion Criteria:

  1. to adalimumab therapy and/or known to adalimumab or its
  2. History of methotrexate intolerance/toxicity
  3. Medical conditions(s) precluding methotrexate dose increase above 15 mg
  4. Had prior exposure to any tumor necrosis factor (TNF) inhibitor, other mechanism of action biologic DMARD (bDMARD) or any systemic biologic agent in general
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
246 participants (actual)

Study arms

  • Active comparator
    Part 1: MTX Escalated Dose

    Methotrexate (MTX) escalated to 20 - 25 mg or highest tolerable dose every week (ew)

    Drug: methotrexate (MTX)

  • Experimental
    Part 1: ADA + MTX

    Adalimumab (ADA) 40 mg every other week (eow) in combination with MTX 15 mg ew

    Drug: methotrexate (MTX) · Biological: adalimumab (ADA)

  • Active comparator
    Part 2: MTX Escalated Dose

    Participants achieving minimal disease activity (MDA) at Week 16 on MTX escalated to 20 -25 mg or highest tolerable dose ew, continued with the same MTX dose

    Drug: methotrexate (MTX)

  • Active comparator
    Part 2: ADA + MTX Escalated Dose

    Participants not achieving MDA at Week 16 on MTX escalated to 20 - 25 mg or highest tolerable dose ew, received ADA 40 mg eow in combination with MTX 20 - 25 mg or highest tolerable dose ew

    Drug: methotrexate (MTX) · Biological: adalimumab (ADA)

  • Experimental
    Part 2: ADA

    Participants achieving MDA at Week 16 on ADA 40 mg eow plus MTX 15 mg ew, had MTX completely withdrawn at Week 16 and continued receiving ADA as monotherapy

    Biological: adalimumab (ADA)

  • Experimental
    Part 2: ADA ew + MTX

    Participants not achieving MDA at Week 16 on ADA 40 mg eow plus MTX 15 mg ew, had ADA escalated to 40 mg ew in combination with MTX 15 mg ew

    Drug: methotrexate (MTX) · Biological: adalimumab (ADA)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Minimal Disease Activity (MDA) (Non-responder Imputation [NRI]) (Part 1)

    Minimal disease activity (MDA) for psoriatic arthritis (PsA) was defined as fulfilling at least 5 of the following 7 criteria: tender and swollen joint counts (TJC) ≤ 1 (out of TJC68 assessed in this study), swollen joint count (SJC) ≤ 1 (out of SJC66 assessed in this study), Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3; Patient's assessment of pain visual analogue scale (VAS) ≤ 15, Patient's global assessment of disease activity (PtGA) VAS ≤ 20, Health Assessment Questionnaire Disability Index (HAQ-DI) score ≤ 0.5, and tender entheseal points ≤ 1 (out of 8 assessed in this study).

    Time frame: Week 16

Secondary outcomes

  1. Change in Dermatology Life Quality Index (DLQI) Score From Baseline (Part 1)

    The Dermatology Life Quality Index (DLQI) score is a measure of participant's quality of life (QOL) related to skin disease.The DLQI questionnaire consists of 10 questions concerning participants' perception of the impact of skin diseases on different aspects of their health related QOL over the last week. The items of the DLQI encompass aspects such as symptoms and feelings, daily activities, leisure, work or school, personal relationships and the side effects of treatment. The range of possible DLQI scores is 0 to 30, with a score of 0 indicating no effect at all on a participant's life and a score of 30 indicating extremely large effect on participant's life. A decrease in DLQI score indicates improvement.

    Time frame: From Day 1 to Week 16

  2. Change in Tender Dactylitic Digit Count From Baseline for Participants With Presence of Dactylitis at Baseline (Part 1)

    Hands and feet bilaterally were assessed for the presence/absence of dactylitis and associated tenderness for participants with presence of dactylitis at baseline. The tender dactylitic digit count is equal to the number of swollen and painful digits (range 0 to 20). A decrease indicates improvement.

    Time frame: From Day 1 to Week 16

  3. Change in Disease Activity Score 28 (DAS28)-C-reactive Protein (CRP) Score From Baseline (Part 1)

    The Disease Activity Score 28 (DAS28) is a validated index of rheumatoid arthritis disease activity but is also used in PsA clinical trials. DAS28 is a composite score calculated using a mathematical formula based on the scores for these scales. DAS28 includes tender and swollen joint counts, PtGA, and acute phase reactant (CRP in this study). DAS28 scores range from 0 to 10, with higher scores indicating more disease activity. A larger negative change in the DAS28 score indicates greater improvement.

    Time frame: From Day 1 to Week 16

  4. Change in Psoriatic Arthritis Impact of Disease Score (PsAID) Score From Baseline (Part 1)

    Psoriatic Arthritis Impact of Disease Score (PsAID) was developed by an European League Against Rheumatism (EULAR) initiative and is a validated patient self-reported tool to assess the impact of PsA on the participant's life. The PsAID is a composite score calculated using a mathematical formula based on the scores for each component. PsAID-9 was developed for clinical trials and was used in this study. The PsAID-9 is calculated based on 9 Numerical rating scales (NRS) questions that include pain, fatigue, skin, work and/or leisure activities, function, discomfort, sleep, coping, and anxiety). Each NRS is assessed as a number between 0 and 10. PsAID scores range from 0 to 10, with higher scores indicating worse status. A larger negative change in the PsAID-9 score indicates greater improvement.

    Time frame: From Day 1 to Week 16

  5. Percentage of Participants Achieving American College of Rheumatology (ACR) 20/50/70 Response (Part 1)

    The ACR is a standard criteria originally developed to measure the effectiveness of various arthritis medications or treatments in clinical trials for RA, but is also widely used in PsA. The ACR measures improvement in tender joint count (TJC) or swollen joint count (SJC), and improvement in at least 3 of the following 5 parameters: Patient Global Assessment (PtGA), Physician's Global Assessment of Disease Activity (PhGA), physical function (using HAQ-DI) and acute phase reactant (using CRP). ACR 20/50/70 response is achieved if ≥ 20%/≥ 50%/≥ 70% improvement in tender joint count (TJC) or swollen joint count (SJC) as well as a ≥ 20%/≥ 50%/≥ 70% improvement in ≥ 3 of the other 5 parameters.

    Time frame: Week 16

  6. Change in Leeds Enthesitis Index (LEI) From Baseline (Part 1) for Participants With Presence of LEI at Baseline

    The Leeds Enthesitis Index (LEI) is an enthesitis measure developed specifically for PsA and assesses the presence or absence of tenderness at the following 3 bilateral enthesial sites: medial femoral condyles, lateral epicondyles of the humerus, and Achilles tendon insertions for participants with presence of LEI at baseline.Tenderness on examination is recorded as either present (1) or absent (0) for each of the 6 sites, for an overall score range of 0 to 6. A decrease in LEI indicates improvement.

    Time frame: From Day 1 to Week 16

  7. Percentage of Participants in MDA in Part 2 of the Study (Week 32)

    MDA for PsA was defined as fulfilling at least 5 of the following 7 criteria: TJC ≤ 1 (out of TJC68 assessed in this study), SJC ≤ 1 (out of SJC66 assessed in this study), PASI ≤ 1 or BSA ≤ 3; Patient's assessment of pain VAS ≤ 15, PtGA VAS ≤ 20, HAQ-DI score ≤ 0.5, and tender entheseal points ≤ 1 (out of 8 assessed in this study).

    Time frame: Week 32

  8. Change in Psoriatic Arthritis Disease Activity Score (PASDAS) From Baseline (Part 1)

    Psoriatic Arthritis Disease Activity Score (PASDAS) is a weighted disease activity measure developed specifically for PsA. It includes PhGA, PtGA, SF-36 PCS, SJC, TJC, Leeds enthesitis count, tender dactylitic count and hsCRP lab test. The PASDAS is a composite score calculated using a mathematical formula based on the scores for each component. The PASDAS is unitless, with a typical score range between 0 and 10. Smaller values on PASDAS indicate a better condition; a negative change from baseline indicates improvement. .

    Time frame: From Day 1 to week 16

  9. Change in Short Form Health Survey 36 (SF-36) Score From Baseline (Part 1)

    The Short Form Health Survey 36 (SF-36) is a generic measure to assess participant's general health/well-being (health related quality of life); short version 2 (SF-36v2) was used. SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise physical component of the SF-36. Scores on each item were summed and averaged (PCS; range = 0-100). Items 5-8 comprise mental component of the SF-36. Scores on each item were summed and averaged (mental component score \[MCS\]; range = 0-100). Larger values on SF-36 indicate a better condition. A positive change from Baseline in either PCS or MCS indicates improvement.

    Time frame: From Day 1 to Week 16

  10. Change in HAQ-DI Score From Baseline (Part 1)

    The HAQ-DI is a standardized measure of physical function in arthritis. The HAQ-DI questionnaire contains 20 items divided into 8 domains that measure: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline indicates improvement.

    Time frame: From Day 1 to Week 16

  11. Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75/90/100 Response Among Participants With BSA Greater Than or Equal to 3% at Baseline (Part 1)

    Psoriasis Area and Severity Index (PASI) provides a quantitative assessment of psoriasis lesional burden based on the amount of body surface area involved and the degree of severity of erythema, induration, and scale, weighted by body part. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. 75/90/100 denotes greater than or equal to 75%/90%/100% improvement in PASI score. A 100% reduction is considered complete clearance of psoriasis.

    Time frame: Week 16

  12. Change in Disease Activity in Psoriatic Arthritis Score (DAPSA) Score From Baseline (Part 1)

    Disease Activity in Psoriatic Arthritis Score (DAPSA) score is a the sum of swollen joint count (66 joints), tender joint count (68 joints), CRP (mg/dL), Patient's Assessment of Pain (on a 10-unit VAS;0=no pain, 10=worst possible pain), and Patient's Global Assessment of Disease Activity (arthritis, on a 10-unit VAS; 0 to 100 centimeter \[cm\] VAS, 0=excellent and 10=poor). Change from baseline in DAPSA measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates worsening of disease activity.

    Time frame: From Day 1 to Week 16

07

Results

Posted Nov 23, 2020

Participant flow

There were 246 participants randomized; 1 participant did not receive study medication. Upon completion of Part 1, eligible participants continued to Part 2, so no additional participants were enrolled in Part 2.

Part 1
Participant flow — Part 1
MilestonePart 1: MTX Escalated DosePart 1: ADA + MTXPart 2: MTX Escalated DosePart 2: ADA +MTX Escalated DosePart 2: ADAPart 2: ADA ew + MTX
Started1221230000
Completed1101170000
Not completed1260000
Withdrew: Adverse event230000
Withdrew: Withdrawal consent810000
Withdrew: Lost to follow-up100000
Withdrew: Lack of efficacy120000
Part 2
Participant flow — Part 2
MilestonePart 1: MTX Escalated DosePart 1: ADA + MTXPart 2: MTX Escalated DosePart 2: ADA +MTX Escalated DosePart 2: ADAPart 2: ADA ew + MTX
Started0015955463
Completed0015915257
Not completed000426
Withdrew: Adverse event000112
Withdrew: Withdrawal consent000211
Withdrew: Lost to follow-up000100
Withdrew: Lack of efficacy000003

Outcome measures

PrimaryPercentage of Participants Achieving Minimal Disease Activity (MDA) (Non-responder Imputation [NRI]) (Part 1)

Minimal disease activity (MDA) for psoriatic arthritis (PsA) was defined as fulfilling at least 5 of the following 7 criteria: tender and swollen joint counts (TJC) ≤ 1 (out of TJC68 assessed in this study), swollen joint count (SJC) ≤ 1 (out of SJC66 assessed in this study), Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3; Patient's assessment of pain visual analogue scale (VAS) ≤ 15, Patient's global assessment of disease activity (PtGA) VAS ≤ 20, Health Assessment Questionnaire Disability Index (HAQ-DI) score ≤ 0.5, and tender entheseal points ≤ 1 (out of 8 assessed in this study).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Minimal Disease Activity (MDA) (Non-responder Imputation [NRI]) (Part 1)
percentage of participantsPart 1: MTX Escalated DosePart 1: ADA + MTX
Percentage of Participants Achieving Minimal Disease Activity (MDA) (Non-responder Imputation [NRI]) (Part 1)13.1 (7.1 to 19.1)41.5 (32.8 to 50.2)
Statistical analysis
  • Part 1: MTX Escalated Dose vs Part 1: ADA + MTX · Cochran-Mantel-Haenszel · p = < 0.001 · Point estimate difference: 28.3 · 95% CI 17.8 to 38.9Adjusted for the stratification factor which is the duration of prior MTX 15 mg ew use of ≤ 3 months or \> 3 months.
SecondaryChange in Dermatology Life Quality Index (DLQI) Score From Baseline (Part 1)

The Dermatology Life Quality Index (DLQI) score is a measure of participant's quality of life (QOL) related to skin disease.The DLQI questionnaire consists of 10 questions concerning participants' perception of the impact of skin diseases on different aspects of their health related QOL over the last week. The items of the DLQI encompass aspects such as symptoms and feelings, daily activities, leisure, work or school, personal relationships and the side effects of treatment. The range of possible DLQI scores is 0 to 30, with a score of 0 indicating no effect at all on a participant's life and a score of 30 indicating extremely large effect on participant's life. A decrease in DLQI score indicates improvement.

Time frame:
From Day 1 to Week 16
Reported as:
Least squares mean · score on a scale
Change in Dermatology Life Quality Index (DLQI) Score From Baseline (Part 1)
score on a scalePart 1: MTX Escalated DosePart 1: ADA + MTX
Change in Dermatology Life Quality Index (DLQI) Score From Baseline (Part 1)-3.1 (-3.85 to -2.30)-5.9 (-6.70 to -5.20)
SecondaryChange in Tender Dactylitic Digit Count From Baseline for Participants With Presence of Dactylitis at Baseline (Part 1)

Hands and feet bilaterally were assessed for the presence/absence of dactylitis and associated tenderness for participants with presence of dactylitis at baseline. The tender dactylitic digit count is equal to the number of swollen and painful digits (range 0 to 20). A decrease indicates improvement.

Time frame:
From Day 1 to Week 16
Reported as:
Least squares mean · count of fingers/ toes with dactylitis
Change in Tender Dactylitic Digit Count From Baseline for Participants With Presence of Dactylitis at Baseline (Part 1)
count of fingers/ toes with dactylitisPart 1: MTX Escalated DosePart 1: ADA + MTX
Change in Tender Dactylitic Digit Count From Baseline for Participants With Presence of Dactylitis at Baseline (Part 1)-0.9 (-1.48 to -0.41)-2.8 (-3.35 to -2.23)
SecondaryChange in Disease Activity Score 28 (DAS28)-C-reactive Protein (CRP) Score From Baseline (Part 1)

The Disease Activity Score 28 (DAS28) is a validated index of rheumatoid arthritis disease activity but is also used in PsA clinical trials. DAS28 is a composite score calculated using a mathematical formula based on the scores for these scales. DAS28 includes tender and swollen joint counts, PtGA, and acute phase reactant (CRP in this study). DAS28 scores range from 0 to 10, with higher scores indicating more disease activity. A larger negative change in the DAS28 score indicates greater improvement.

Time frame:
From Day 1 to Week 16
Reported as:
Least squares mean · score on a scale
Change in Disease Activity Score 28 (DAS28)-C-reactive Protein (CRP) Score From Baseline (Part 1)
score on a scalePart 1: MTX Escalated DosePart 1: ADA + MTX
Change in Disease Activity Score 28 (DAS28)-C-reactive Protein (CRP) Score From Baseline (Part 1)-0.9 (-1.08 to -0.65)-2.0 (-2.16 to -1.75)
SecondaryChange in Psoriatic Arthritis Impact of Disease Score (PsAID) Score From Baseline (Part 1)

Psoriatic Arthritis Impact of Disease Score (PsAID) was developed by an European League Against Rheumatism (EULAR) initiative and is a validated patient self-reported tool to assess the impact of PsA on the participant's life. The PsAID is a composite score calculated using a mathematical formula based on the scores for each component. PsAID-9 was developed for clinical trials and was used in this study. The PsAID-9 is calculated based on 9 Numerical rating scales (NRS) questions that include pain, fatigue, skin, work and/or leisure activities, function, discomfort, sleep, coping, and anxiety). Each NRS is assessed as a number between 0 and 10. PsAID scores range from 0 to 10, with higher scores indicating worse status. A larger negative change in the PsAID-9 score indicates greater improvement.

Time frame:
From Day 1 to Week 16
Reported as:
Least squares mean · score on a scale
Change in Psoriatic Arthritis Impact of Disease Score (PsAID) Score From Baseline (Part 1)
score on a scalePart 1: MTX Escalated DosePart 1: ADA + MTX
Change in Psoriatic Arthritis Impact of Disease Score (PsAID) Score From Baseline (Part 1)-1.7 (-2.09 to -1.28)-3.3 (-3.73 to -2.95)
SecondaryPercentage of Participants Achieving American College of Rheumatology (ACR) 20/50/70 Response (Part 1)

The ACR is a standard criteria originally developed to measure the effectiveness of various arthritis medications or treatments in clinical trials for RA, but is also widely used in PsA. The ACR measures improvement in tender joint count (TJC) or swollen joint count (SJC), and improvement in at least 3 of the following 5 parameters: Patient Global Assessment (PtGA), Physician's Global Assessment of Disease Activity (PhGA), physical function (using HAQ-DI) and acute phase reactant (using CRP). ACR 20/50/70 response is achieved if ≥ 20%/≥ 50%/≥ 70% improvement in tender joint count (TJC) or swollen joint count (SJC) as well as a ≥ 20%/≥ 50%/≥ 70% improvement in ≥ 3 of the other 5 parameters.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology (ACR) 20/50/70 Response (Part 1)
percentage of participantsPart 1: MTX Escalated DosePart 1: ADA + MTX
ACR 2032.8 (24.5 to 41.1)67.5 (59.2 to 75.8)
ACR 5016.4 (9.8 to 23.0)45.5 (36.7 to 54.3)
ACR 708.2 (3.3 to 13.1)30.9 (22.7 to 39.1)
SecondaryChange in Leeds Enthesitis Index (LEI) From Baseline (Part 1) for Participants With Presence of LEI at Baseline

The Leeds Enthesitis Index (LEI) is an enthesitis measure developed specifically for PsA and assesses the presence or absence of tenderness at the following 3 bilateral enthesial sites: medial femoral condyles, lateral epicondyles of the humerus, and Achilles tendon insertions for participants with presence of LEI at baseline.Tenderness on examination is recorded as either present (1) or absent (0) for each of the 6 sites, for an overall score range of 0 to 6. A decrease in LEI indicates improvement.

Time frame:
From Day 1 to Week 16
Reported as:
Least squares mean · score on a scale
Change in Leeds Enthesitis Index (LEI) From Baseline (Part 1) for Participants With Presence of LEI at Baseline
score on a scalePart 1: MTX Escalated DosePart 1: ADA + MTX
Change in Leeds Enthesitis Index (LEI) From Baseline (Part 1) for Participants With Presence of LEI at Baseline-1.1 (-1.43 to -0.75)-1.9 (-2.22 to -1.54)
SecondaryPercentage of Participants in MDA in Part 2 of the Study (Week 32)

MDA for PsA was defined as fulfilling at least 5 of the following 7 criteria: TJC ≤ 1 (out of TJC68 assessed in this study), SJC ≤ 1 (out of SJC66 assessed in this study), PASI ≤ 1 or BSA ≤ 3; Patient's assessment of pain VAS ≤ 15, PtGA VAS ≤ 20, HAQ-DI score ≤ 0.5, and tender entheseal points ≤ 1 (out of 8 assessed in this study).

Time frame:
Week 32
Reported as:
Number · percentage of participants
Percentage of Participants in MDA in Part 2 of the Study (Week 32)
percentage of participantsPart 2: MTX Escalated DosePart 2: ADA + MTX Escalated DosePart 2: ADAPart 2: ADA ew + MTX
Percentage of Participants in MDA in Part 2 of the Study (Week 32)66.7 (42.8 to 90.5)54.9 (44.7 to 65.2)80.4 (69.5 to 91.3)29.8 (17.9 to 41.7)
SecondaryChange in Psoriatic Arthritis Disease Activity Score (PASDAS) From Baseline (Part 1)

Psoriatic Arthritis Disease Activity Score (PASDAS) is a weighted disease activity measure developed specifically for PsA. It includes PhGA, PtGA, SF-36 PCS, SJC, TJC, Leeds enthesitis count, tender dactylitic count and hsCRP lab test. The PASDAS is a composite score calculated using a mathematical formula based on the scores for each component. The PASDAS is unitless, with a typical score range between 0 and 10. Smaller values on PASDAS indicate a better condition; a negative change from baseline indicates improvement. .

Time frame:
From Day 1 to week 16
Reported as:
Least squares mean · score on a scale
Change in Psoriatic Arthritis Disease Activity Score (PASDAS) From Baseline (Part 1)
score on a scalePart 1: MTX Escalated DosePart 1: ADA + MTX
Change in Psoriatic Arthritis Disease Activity Score (PASDAS) From Baseline (Part 1)-1.2 (-1.46 to -0.86)-2.8 (-3.05 to -2.48)
SecondaryChange in Short Form Health Survey 36 (SF-36) Score From Baseline (Part 1)

The Short Form Health Survey 36 (SF-36) is a generic measure to assess participant's general health/well-being (health related quality of life); short version 2 (SF-36v2) was used. SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise physical component of the SF-36. Scores on each item were summed and averaged (PCS; range = 0-100). Items 5-8 comprise mental component of the SF-36. Scores on each item were summed and averaged (mental component score \[MCS\]; range = 0-100). Larger values on SF-36 indicate a better condition. A positive change from Baseline in either PCS or MCS indicates improvement.

Time frame:
From Day 1 to Week 16
Reported as:
Least squares mean · score on a scale
Change in Short Form Health Survey 36 (SF-36) Score From Baseline (Part 1)
score on a scalePart 1: MTX Escalated DosePart 1: ADA + MTX
SF-36 PCS4.4 (3.07 to 5.73)8.9 (7.58 to 10.15)
SF-36 MCS1.3 (-0.36 to 2.97)4.4 (2.85 to 6.05)
SecondaryChange in HAQ-DI Score From Baseline (Part 1)

The HAQ-DI is a standardized measure of physical function in arthritis. The HAQ-DI questionnaire contains 20 items divided into 8 domains that measure: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline indicates improvement.

Time frame:
From Day 1 to Week 16
Reported as:
Least squares mean · score on a scale
Change in HAQ-DI Score From Baseline (Part 1)
score on a scalePart 1: MTX Escalated DosePart 1: ADA + MTX
Change in HAQ-DI Score From Baseline (Part 1)-0.3 (-0.39 to -0.21)-0.5 (-0.60 to -0.42)
SecondaryPercentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75/90/100 Response Among Participants With BSA Greater Than or Equal to 3% at Baseline (Part 1)

Psoriasis Area and Severity Index (PASI) provides a quantitative assessment of psoriasis lesional burden based on the amount of body surface area involved and the degree of severity of erythema, induration, and scale, weighted by body part. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. 75/90/100 denotes greater than or equal to 75%/90%/100% improvement in PASI score. A 100% reduction is considered complete clearance of psoriasis.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75/90/100 Response Among Participants With BSA Greater Than or Equal to 3% at Baseline (Part 1)
percentage of participantsPart 1: MTX Escalated DosePart 1: ADA + MTX
PASI 7531.0 (21.3 to 40.8)73.1 (63.2 to 82.9)
PASI 9018.4 (10.3 to 26.5)57.7 (46.7 to 68.7)
PASI 1009.2 (3.1 to 15.3)29.5 (19.4 to 39.6)
SecondaryChange in Disease Activity in Psoriatic Arthritis Score (DAPSA) Score From Baseline (Part 1)

Disease Activity in Psoriatic Arthritis Score (DAPSA) score is a the sum of swollen joint count (66 joints), tender joint count (68 joints), CRP (mg/dL), Patient's Assessment of Pain (on a 10-unit VAS;0=no pain, 10=worst possible pain), and Patient's Global Assessment of Disease Activity (arthritis, on a 10-unit VAS; 0 to 100 centimeter \[cm\] VAS, 0=excellent and 10=poor). Change from baseline in DAPSA measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates worsening of disease activity.

Time frame:
From Day 1 to Week 16
Reported as:
Least squares mean · score on a scale
Change in Disease Activity in Psoriatic Arthritis Score (DAPSA) Score From Baseline (Part 1)
score on a scalePart 1: MTX Escalated DosePart 1: ADA + MTX
Change in Disease Activity in Psoriatic Arthritis Score (DAPSA) Score From Baseline (Part 1)-12.1 (-15.57 to -8.69)-28.2 (-31.60 to -24.87)

Adverse events

Collected over All adverse events reported from the time of study medication administration until 70 days following discontinuation of study medication administration have elapsed.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: MTX Escalated Dose0/122 (0%)0/122 (0%)32/122 (26.2%)
Part 1: ADA + MTX0/123 (0%)2/123 (1.6%)24/123 (19.5%)
Part 2: MTX Escalated Dose0/15 (0%)0/15 (0%)5/15 (33.3%)
Part 2: ADA + MTX Escalated Dose0/95 (0%)3/95 (3.2%)25/95 (26.3%)
Part 2: ADA0/54 (0%)1/54 (1.9%)5/54 (9.3%)
Part 2: ADA ew + MTX0/63 (0%)3/63 (4.8%)20/63 (31.7%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPart 1: MTX Escalated DosePart 1: ADA + MTXPart 2: MTX Escalated DosePart 2: ADA + MTX Escalated DosePart 2: ADAPart 2: ADA ew + MTX
LUMBAR VERTEBRAL FRACTUREInjury, poisoning and procedural complications0/1220/1230/150/951/540/63
URETEROLITHIASISRenal and urinary disorders0/1220/1230/150/951/540/63
GASTRIC MUCOSA ERYTHEMAGastrointestinal disorders0/1220/1230/150/950/541/63
GASTRITISGastrointestinal disorders0/1220/1230/150/950/541/63
BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1220/1230/150/950/541/63
UTERINE POLYPReproductive system and breast disorders0/1220/1230/150/950/541/63
ASTHMARespiratory, thoracic and mediastinal disorders0/1220/1230/150/950/541/63
DIVERTICULITISInfections and infestations0/1220/1230/151/950/540/63
SUBCUTANEOUS ABSCESSInfections and infestations0/1220/1230/151/950/540/63
ANKLE FRACTUREInjury, poisoning and procedural complications0/1220/1230/151/950/540/63
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPart 1: MTX Escalated DosePart 1: ADA + MTXPart 2: MTX Escalated DosePart 2: ADA + MTX Escalated DosePart 2: ADAPart 2: ADA ew + MTX
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations11/12210/1230/1513/952/549/63
NAUSEAGastrointestinal disorders11/1225/1231/154/950/541/63
HEADACHENervous system disorders2/12210/1230/150/950/540/63
HEPATITISHepatobiliary disorders0/1220/1231/150/950/540/63
BRONCHITISInfections and infestations0/1220/1231/151/950/540/63
PNEUMONIAInfections and infestations0/1220/1231/150/950/541/63
ALANINE AMINOTRANSFERASE INCREASEDInvestigations0/1220/1231/152/951/543/63
TRANSAMINASES INCREASEDInvestigations0/1220/1231/150/950/541/63
PSORIATIC ARTHROPATHYMusculoskeletal and connective tissue disorders0/1220/1231/150/950/544/63
DRUG INTOLERANCEGeneral disorders8/1220/1230/150/950/540/63

Baseline characteristics

The Intent-To-Treat Part 1 (ITT Part 1) population comprises all participants who were randomized and received at least one dose of the study medication during Part 1.

Age, Continuous
Age, Continuous(years)Part 1: MTX Escalated DosePart 1: ADA + MTXTotal
Mean48.8 ± 12.6951.4 ± 12.2350.1 ± 12.50
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: MTX Escalated DosePart 1: ADA + MTXTotal
Female5964123
Male6359122
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: MTX Escalated DosePart 1: ADA + MTXTotal
Hispanic or Latino272754
Not Hispanic or Latino9596191
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: MTX Escalated DosePart 1: ADA + MTXTotal
American Indian or Alaska Native000
Asian718
Native Hawaiian or Other Pacific Islander011
Black or African American224
White111115226
More than one race246
Unknown or Not Reported000
08

Study locations

60 sites
  • AZ Arthritis & Rheum Research /ID# 161796
    Sun City, Arizona 85351, United States
  • LeJenue Research Associates /ID# 200093
    Miami, Florida 33126, United States
  • Deerbrook Medical Associates /ID# 158655
    Vernon Hills, Illinois 60061, United States
  • Ochsner Clinic Foundation /ID# 155178
    Baton Rouge, Louisiana 70836-6455, United States
  • Clinical Pharmacology Study Gr /ID# 161057
    Worcester, Massachusetts 01605, United States
  • Shores Rheumatology, PC /ID# 162697
    Saint Clair Shores, Michigan 48081, United States
  • Coastal Carolina Health Care /ID# 152088
    New Bern, North Carolina 28562, United States
  • PMG Research of Wilmington LLC /ID# 152089
    Wilmington, North Carolina 28401, United States
  • Altoona Ctr Clinical Res /ID# 152087
    Duncansville, Pennsylvania 16635, United States
  • Metroplex Clinical Research /ID# 162486
    Dallas, Texas 75231, United States
  • Swedish Medical Center /ID# 162051
    Seattle, Washington 98104, United States
  • West Virginia Research Inst /ID# 157815
    South Charleston, West Virginia 25309, United States
  • Royal Prince Alfred Hospital /ID# 153144
    Camperdown, New South Wales 2050, Australia
  • Optimus Clinical Research Pty. /ID# 153145
    Kogarah, New South Wales 2217, Australia
  • Liverpool Hospital /ID# 153147
    Liverpool, New South Wales 2170, Australia
  • BJC Health /ID# 153875
    Paramatta, New South Wales 2150, Australia
  • Box Hill Hospital /ID# 153146
    Melbourne, Victoria 3128, Australia
  • Hospital de Clinicas de Porto Alegre /ID# 152345
    Porto Alegre, Rio Grande Do Sul 90035-903, Brazil
  • Faculdade de Medicina do ABC /ID# 152344
    Santo André, Sao Paulo 09060-870, Brazil
  • MHAT Trimontsium /ID# 152658
    Plovdiv, 4000, Bulgaria
  • Diag Consult Ctr 17 Sofia EOOD /ID# 152657
    Sofia, 1505, Bulgaria
  • Rheumatology Research Assoc /ID# 161600
    Edmonton, Alberta T5M 0H4, Canada
  • Percuro Clinical Research, Ltd /ID# 161601
    Victoria, British Columbia V8V 3M9, Canada
  • Manitoba Clinic /ID# 151939
    Winnipeg, Manitoba R3A 1M3, Canada
  • St. Clare's Mercy Hospital /ID# 159680
    St. John's, Newfoundland and Labrador A1C 5B8, Canada
  • The Waterside Clinic /ID# 151938
    Barrie, Ontario L4M 6L2, Canada
  • Adachi Medicine Prof. Corp /ID# 152575
    Hamilton, Ontario L8N 1Y2, Canada
  • Ctr. de Rheum de l'est du QC /ID# 151937
    Rimouski, Quebec G5L 8W1, Canada
  • Groupe de Recherche en Maladies Osseuses /ID# 205693
    Sainte-foy, Quebec G1V 3M7, Canada
  • Centro de Investigacion en Reumatologia y Especialidades Medicas- CIREEM SAS /ID# 151954
    Bogota, Cundinamarca 110221, Colombia
  • Riesgo de Fractura S.A - CAYRE /ID# 153817
    Bogota, 111121, Colombia
  • San Vicente Fundacion /Id# 171324
    Medellin, 050034, Colombia
  • Revmatolog s.r.o. /ID# 151753
    Jihlava 1, Jihlava 586 01, Czechia
  • Nuselská poliklinika, Revmatologie /ID# 151754
    Prague 4, Praha 4 140 00, Czechia
  • Universitaetsklinik Heidelberg /ID# 152229
    Heidelberg, Baden-Wuerttemberg 69120, Germany
  • Fachpraxis fuer Rheumatologie und Osteologie /ID# 203982
    Bruchhausen-Vilsen, Niedersachsen 27305, Germany
  • Univ Hosp Schleswig-Holstein, Campus Kiel, Klinik furer Innere Medizin /ID# 152231
    Kiel, Schleswig-Holstein 24105, Germany
  • CIRI GmbH /ID# 152228
    Frankfurt, 60590, Germany
  • Hamburger Rheuma I /ID# 164055
    Hamburg, 22391, Germany
  • Universita di Catanzaro Magna Graecia /ID# 152013
    Catanzaro, Calabria 88100, Italy
  • Azienda Ospedaliera Policlinic /ID# 152011
    Rome, 00161, Italy
  • A.O. Universitaria Senese /ID# 152012
    Siena, 53100, Italy
  • McBk Sc /Id# 163089
    Grodzisk Mazowiecki, Mazowieckie 05-825, Poland
  • Centrum Medyczne AMED /ID# 164047
    Warsaw, Mazowieckie 01-518, Poland
  • SANUS Szpital Specjalistyczny /ID# 151988
    Stalowa Wola, Podkarpackie 37-450, Poland
  • ClinicMed Badurski i wspolnicy SJ /ID# 151987
    Bialystok, 15-879, Poland
  • Dr. Ramon L. Ortega-Colon, MD /ID# 152957
    Carolina, 00983, Puerto Rico
  • GCM Medical Group, PSC /ID# 152091
    San Juan, 00917, Puerto Rico
  • Hamad Hospital /ID# 152334
    Doha, Ad Dawhah, Qatar
  • Corporac Sanitaria Parc Tauli /ID# 151759
    Sabadell, Barcelona 08208, Spain
  • Hospital Univ Germans Trias I Pujol /ID# 151760
    Badalona, 08916, Spain
  • Hospital Universitario Reina S /ID# 151761
    Cordoba, 14004, Spain
  • Hospital Manises /ID# 162778
    Manises, 46940, Spain
  • Hospital Univ Canarias /ID# 206489
    Santa Cruz de Tenerife, 38320, Spain
  • Hospital de Viladecans /ID# 163875
    Viladecans, 8840, Spain
  • Royal National Hosp for Rheuma /ID# 152767
    Bath, BA1 1RL, United Kingdom
  • Western General Hospital /ID# 155195
    Edinburgh, EH4 2XU, United Kingdom
  • Altnagelvin Area Hospital /ID# 152766
    Londonderry, BT47 6SB, United Kingdom
  • Central Manchester University /ID# 152765
    Manchester, M13 9WL, United Kingdom
  • Lancashire Care NHS Foundation /ID# 152769
    Preston, BT47 3EN, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Sep 2019, 37 months.

Results were first posted in Nov 2020, 1 year 2 months after primary completion.

Of 33 phase 4 interventional studies under Arthritis, Psoriatic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 37. This study's 37 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2016
First posted
Jun 27, 2016
StartActual
Aug 5, 2016
Primary completionActual
Sep 23, 2019
CompletionActual
Mar 19, 2020
Results first posted
Nov 23, 2020
Last update
Nov 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02814175
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 27, 2016
Start date
Aug 5, 2016
Primary completion
Sep 23, 2019
Completion
Mar 19, 2020
Results posted
Nov 23, 2020
Last update
Nov 23, 2020

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methotrexate · Adalimumab

Start the discussion